US 12,435,158 B2
Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders
Rosanne Dunn, Sydney (AU)
Assigned to HAEMALOGIX LTD, Sydney (AU)
Filed by HaemaLogiX, Sydney (AU)
Filed on Aug. 12, 2022, as Appl. No. 17/819,483.
Application 17/819,483 is a division of application No. 16/970,991, granted, now 11,447,571, previously published as PCT/AU2019/050137, filed on Feb. 20, 2019.
Claims priority of application No. 2018900534 (AU), filed on Feb. 20, 2018.
Prior Publication US 2023/0174675 A1, Jun. 8, 2023
Int. Cl. C07K 16/00 (2006.01); A61P 35/00 (2006.01); C07K 16/42 (2006.01)
CPC C07K 16/42 (2013.01) [A61P 35/00 (2018.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 6 Claims
 
1. An anti LMA binding protein having an antigen binding domain that binds to LMA, the binding protein comprising:
a VH comprising a CDR1 having the amino acid sequence of SEQ ID NO: 1, a CDR2 having the amino acid sequence of SEQ ID NO: 2 and a CDR3 having the amino acid sequence of SEQ ID NO: 3; and,
a first VL comprising a CDR1 having the amino acid sequence of SEQ ID NO: 6, a CDR2 having the amino acid sequence of SEQ ID NO: 7, and a CDR3 having the amino acid sequence of SEQ ID NO: 8; or,
a second VL comprising a CDR1 having the amino acid sequence of SEQ ID NO: 11, a CDR2 having the amino acid sequence of SEQ ID NO: 12, and a CDR3 having the amino acid sequence of SEQ ID NO: 13.